Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 65Nivolumab 56Ipilimumab 34Specimen Handling 23Magnetic Resonance Spectroscopy 21Cyclophosphamide 17Biopsy 13Radiosurgery 12relatlimab 11fludarabine 11binimetinib 11Opdualag 11CTLA-4 Antigen 11trametinib 10fludarabine phosphate 8dabrafenib 8lifileucel 7encorafenib 7aldesleukin 7atezolizumab 6Interleukin-2 6cemiplimab 5X-Rays 5Paclitaxel 5Immunoglobulin G 5Blood Specimen Collection 5Taxes 4Radiotherapy 4Pemetrexed 4Gemcitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Lidocaine, Prilocaine Drug Combination × 90 days × Clear all
NCT06223659 2026-03-10

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
100 enrolled
Dermatologic

Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡